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ABSTRACT 
 
Two new cyclic lipodepsipeptides named pseudodesmin A and B have been isolated from 
Pseudomonas bacteria collected from the mucus layer in the skin of the black belly salamander. 
Both compounds show moderate antibacterial activity against Gram positive bacteria, including 
MRSA. Complete 1H, 13C and 15N NMR assignment of both compounds afforded their covalent 
structure and served to guide the analysis of LC-MS and X-ray diffraction data from which the 
final stereochemistry could be established. Both molecules can be categorized as new members 
of the viscosin group of cyclic lipodepsipeptides.  
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1. Introduction 
 
Cyclic lipodepsipeptides (CLPs) are secondary metabolites produced mainly by Pseudomonas 
bacteria1,2, and are of interest as they display potential anti-microbial activity. They consist of an 
oligopeptide chain that forms a cyclic structure via a lactone (or so-called depsi) bond involving the C-
terminus, and a long fatty acid chain that is connected to the exocyclic N-terminus. CLPs are believed 
to have several extracellular functions, including surface motility, biosurfactant activity and 
antimicrobial activity. Because CLPs are not bound to the rules of ribosomal synthesis2, uncommon or 
modified amino acids, including D-amino acids, are often present. They have been classified into 
several groups, including the viscosin group, the amphisin group, the syringomycin group and the 
tolaasin group1,2. With the exception of the latter, the peptide chain length within each group is the 
same and a similar sequence distribution pattern in hydrophobic and hydrophilic residues can be 
observed. The viscosin group comprises viscosin3, viscosinamide4, White Line Inducing Principle 
(WLIP)5, massetolide A-H6 and pseudophomin A and B7, which all consist of 9 amino acid residues, 7 
of which form the cyclic structure via lactone bond formation between the C-terminus and the side 
chain of a D-allo-Thr at position 3. They are produced by several Pseudomonas species, including P. 
viscosa8, P. libanensis9 (viscosin), different strains of P. fluorescens (viscosin10, viscosinamide4, the 
massetolides11 and pseudophomins7) and P. reactans (WLIP5).  
Here we report the isolation, biological activity and conformation of two new CLPs, pseudodesmin 
A and B (Figure 1). They originate from Pseudomonas bacteria living in the mucus layer of 
salamanders of the Plethodontidae family and are shown to display moderate antibiotic activities. Full 
elucidation of the covalent structure was achieved through NMR, LC-MS and X-Ray diffraction 
analysis, revealing pseudodesmin A and B to be new members of the viscosin group. For certain 
viscosin group members, transmembrane pore formation has been proposed as the most likely 
biological mode of action12,13. Using the crystal structure of pseudodesmin A, potential links between 
the structure and this mode of action are discussed. 
 
 
2. Results 
 
2.1. Pseudodesmin A and B display moderate antibacterial and antiviral activity 
 
The newly isolated compounds were scrutinized for biological activity against a series of Tier one 
pathogens. The results of the antibiotic, antimycotic, antiviral and cytotoxic screenings are presented 
in Tables 1 and 2. Pseudodesmin A and B both possess bacteriostatic properties against Gram positive 
bacteria, including several resistant strains. However, no bacteriocidal effects were observed at 
concentrations up to 25 µg/ml (maximum test dosage). Only a modest antiviral activity against HIV1 
and VZV and some cytostatic activity can be observed for the mixture of pseudodesmin A and B, 
whereas no significant antimycotic activity is observed.  
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2.2. Structure elucidation of pseudodesmin A and B 
 
Initial LC-MS studies revealed the molecular weights of pseudodesmin A and B to be 1124.2 Da and 
1110.2 Da respectively. Using MS/MS analysis data alone, no conclusive proposal for the molecular 
structure could be made, however the presence of a cyclic oligopeptide fragment was already 
suspected. In addition, the absence of a free amino group was revealed from a negative response to a 
ninhydrine colouring test. The oligopeptide nature was confirmed using NMR spectroscopy. The 2D 
TOCSY spectrum showed correlations between amide resonances and aliphatic spin systems 
characteristic for amino acid moieties. Full assignment and structure confirmation was achieved in a 
2mM acetonitrile solution. Combined analysis of a 2D DQF-COSY and a 1H-13C-HSQC spectrum 
revealed 10 separate spin systems for pseudodesmin A, corresponding to 9 amino acid residues (1 Glx, 
3 Leu’s, 1 Thr, 2 Ser’s, 1 Val and 1 Ile) and a 2-hydroxynonyl (R) spin system. The sequence of these 
residues was established through a 200 ms NOESY spectrum from sequential Hα to HN nOe’s, 
including a connection between the αCH2 of the 2-hydroxynonyl moiety and the HN of Leu1. In 
addition, nOe contacts between the γ protons of the Glx spinsystem to two resonances in the amide 
region of the spectrum that exclusively correlate with each other in COSY and TOCSY spectra, 
established the Glx residue as a Gln. The primary structure of pseudodesmin A was thus established as 
R-Leu-Gln-Thr-Val-Leu-Ser-Leu-Ser-Ile. Finally, the 1H-13C-gHMBC allowed to assign all the 
carbonyl 13C resonances through 2JC’H coupling correlations with the HN or Hα resonances. The 2-
hydroxynonyl spin system could be assigned to a 3-hydroxydecanoic acid (HDA) moiety. Most 
importantly, a clear 3JCH correlation between the Thr3 Hβ and the Ile9 carbonyl resonances 
unambiguously demonstrated the presence of a lactone bond, revealing a cyclic heptapeptide structure 
with two exocyclic residues at the N-terminus. The final covalent structure thus derived (Figure 1) was 
in agreement with the molecular weight previously determined by LC-MS. Finally, 15N assignments 
were established at natural abundance via a 2D 1H-15N gHSQC at 700 MHz. Structure elucidation and 
NMR assignment of pseudodesmin B were obtained in a similar fashion and revealed the substitution 
of the Ile9 residue for a second Val residue as the only difference with pseudodesmin A, in accordance 
with the 14 Da mass difference. The complete assignments of both molecules are collected in Tables 3 
and 4, while 1D 1H and 2D HSQC spectra are provided in the supplementary data. 
To establish the stereochemistry, pseudodesmin A was subjected to total hydrolysis followed by 
derivatization of the free amino acids with Marfey’s reagent14 and LC-MS analysis. The presence of 
two L-Leu, one D-Leu, two D-Ser, one D-allo-Thr, one D-Val and one L-Ile could be established. 
After lengthy crystallization trials, a crystal structure of pseudodesmin A was obtained from 
acetonitrile solution, which finally revealed the absolute configuration of the remaining stereocentres 
((3R)-HDA, D-Gln2 and the D-Leu at position 5), the LC-MS being critical to distinguish between 
both possible enantiomers of the crystal structure. Due to limited material, pseudodesmin B was not 
subjected to total hydrolysis for chromatographic analysis and crystallization trials remained 
unsuccessful. However, except for the Ile/Val substitution, no significant differences in chemical shifts 
and 3JHNHα scalar couplings between pseudodesmin A and B can be observed. Therefore, we are 
confident that the stereochemistry is identical, since one or multiple inversions of a single stereocentre 
would undoubtedly have a strong impact on the overall conformation and thus on the aforementioned 
conformation sensitive NMR parameters. 
Both products were subjected to high resolution mass spectrometry analysis, of which the 
experimental details and full results are described in the supplementary data. This was performed at 
the Research Institute of Chromatography in Kortrijk, Belgium. The analysis provided a molecular 
weight of the protonated ion [M·+H]+· of 1125.71396 Da for pseudodesmin A and 1111.70019 Da for 
pseudodesmin B, which is in good agreement with the respective molecular formulas of C54H96N10O15 
and C53H94N10O15. 
 
2.3 The crystal structure of pseudodesmin A 
 
The crystal structure of pseudodesmin A is presented in Figure 2, while general crystallographic 
parameters are provided in Table 5. Crystallographic data (excluding structure factors) have been 
deposited with the Cambridge Crystallographic Data Centre as supplementary publication CCDC 
685601. Copies of the data can be obtained, free of charge, on application to CCDC, 12 Union Road, 
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Cambridge CB2 1EZ, UK, (fax: +44-(0)1223-336033 or e-mail: deposit@ccdc.cam.ac.uk). Based on 
the φ/ψ angles collected in Table 6, the conformation mainly consists of a short left-handed α-helix 
ranging from D-Gln2 to D-Leu5. The helix is stabilized by two i+4→i hydrogen bonds (Leu5 NH → 
Leu1 CO and Ser6 NH → Gln2 CO) (Table 7) and is preceded by a type II β turn over the L-Leu1–D-
Gln2 dipeptide and followed by a type I’ β-turn over D-Leu5–D-Ser6. Both are accompanied by the 
characteristic hydrogen bonds, involving the NH of Thr3 with the CO of the HDA moiety and the NH 
of Leu7 and the CO of Val4 respectively. The switch to the L-configuration at Leu7 ends the αL-helix, 
the main chain veering away right-handedly. The alternating L-D-L configuration in the Leu7-Ile9 
tripeptide allows the backbone to loop back and brings the carboxylic end of the main chain in an 
adequate position to form the lactone bond with the Thr3 side chain (Figure 3). The loop thus locks the 
N- and C-terminal ends of the αL-helix together. It also caps the Thr3 and Val4 CO’s by forming 
additional hydrogen bonds with the Ser8 NH and Leu7 NH respectively. The Ile9 NH is not involved 
in any intramolecular hydrogen bond. All intramolecular and further intermolecular hydrogen bonds 
are listed in Table 7. Some of the intermolecular hydrogen bonds involve a single water molecule that 
acts as a hydrogen bond mediator between the C-terminal end of one molecule, where it caps the free 
carbonyl groups of Ser6 and Leu7, and the N-terminal end of the next one, where it interacts with the 
amide of Leu1.  
The organization of the individual molecules is such that the hydrophobic side chains are packed 
together, delimiting large empty spaces between different units. The long alkyl chain of the HDA 
extends out into these spaces, where the high B-factors at the end of this chain are indicative of a 
higher degree of motional freedom. 
 
3. Discussion 
 
3.1 Biological activity of the pseudodesmins and comparison with the viscosin group 
 
The current need for new lead compounds and antibiotic agents that circumvent the increasing levels 
of resistance against antibacterial and antiviral agents remains an important motivation in the search 
for new natural products with relevant biological activity. Pseudodesmin A and B are both mainly 
active against Gram positive bacteria such as VRE and MRSA. However, they are generally less 
potent and their inhibition spectrum is not as broad as standard antibiotics such as vancomycin. They 
also do not possess any noteworthy antifungal, antiviral or cytostatic activity. Pseudodesmin A and B 
are very similar to a collection of CLPs known as the viscosin group1 (Figure 4). A prominent 
distinction with all but one (viscosinamide) of the other members in this group is that they have a 
glutamine rather than a glutamic acid at position 2. It can be noted that pseudodesmin A differs from 
WLIP only by this D-Glu/D-Gln substitution. Pseudodesmin A can thus be considered as WLIP-
amide. Compared to viscosinamide, it only differs with respect to the stereochemistry of the Leu at 
position 5, being D rather than L. With an L-Val at position 9 pseudodesmin B differs by at least two 
substitutions from any previously known viscosin group member: WLIP (Ile9 and Glu2) and 
viscosinamide (L-Leu5 and Ile9). Only one other member, massetolide E, features an L-Val9, 
however, it has an L-Leu rather than a D-Leu at position 5 and a D-Glu instead of D-Gln.  
Viscosin has been described by Kochi et al8 to have no effect against most of the Gram positive and 
Gram negative bacteria that they tested. Later, both viscosin and the massetolides were reported to 
possess significant activity against Mycobacterium tuberculosis and Mycobacterium avium-
intracellulare, but not against E. coli and S. aureus6. The latter is a significant difference with the 
pseudodesmins, which could possibly be correlated with the opposite stereochemistry of the Leu5 
residue. Viscosinamide has been found to be mainly active against plant pathogens such as 
Rhizoctonia solani and Pythium ultimum4,13. While no antifungal activity for the pseudodesmins was 
observed, the pseudophomins have been found to be responsible for the antifungal activity of P. 
fluorescens7. Because the latter compounds were not confronted against the same pathogens used here, 
a direct comparison can unfortunately not be made. WLIP was initially found to inhibit the brown 
blotch disease in Agaricus bisporus caused by Pseudomonas tolaasii15 and only later subjected to a 
more thorough biological screening against fungi and bacteria12. It was shown to display the same 
properties as the pseudodesmins in that it is mainly active against Gram positive but not against Gram 
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negative bacteria. C. albicans, C. neoformans and E. coli, the only common pathogens in the WLIP 
and pseudodesmin screenings, were also found not to be inhibited by WLIP. 
 
3.2 Conformation of pseudodesmin A and comparison to other CLPs 
 
From the alignment of sequences in the viscosin group (Figure 4), two subsets can be distinguished 
depending on whether Leu5 has an L (viscosin, viscosinamide and massetolides A-H) or D (WLIP, the 
pseudophomins and the pseudodesmins) configuration. This is motivated by the fact that other 
variations affect the nature of the side chains rather than the backbone. Since three dimensional 
structures have only been determined for the D-Leu type viscosin members, the structural impact of 
the D/L variation can unfortunately not yet be assessed. Given the high sequence similarity within the 
D-Leu subset, it is of no surprise that the crystal structure of pseudodesmin A is practically identical to 
those of WLIP16 and the pseudophomins17. In all cases, the RMSD between the oligopeptide backbone 
and Thr3 side chain atom coordinates (29 atoms) is smaller than 0.03 Å. Consequently, the short αL-
helix present in pseudodesmin A is also present in these structures even though it was never 
recognized as such before. An NMR solution structure has been reported for WLIP as well5, which 
was described to be significantly different from the crystal structure. Since the coordinates of this 
structure are not available, further comparisons cannot be made.  
Helical structures in cyclic lipodepsipeptides have also been described outside the viscosin group. 
Amphisin18 and tensin19 (Figure 4) are CLPs very similar to the viscosin group, but have a ring 
structure built out of 9 residues instead of 7. There are some substitutions of residues, but the overall 
pattern of hydrophobic and hydrophilic amino acids and D and L chirality is maintained. A crystal 
structure for both these CLPs has been reported and both possess an αL-helix of equal number of 
residues to pseudodesmin A, while the extra residues are accommodated in the C-terminal loop. The 
RMSD of the backbone of this helix to the pseudodesmin A structure measured starting from the 
amide of residue 2 to the carbonyl of residue 5 (12 atoms) is only 0.15 Å for amphisin and 0.12 Å for 
tensin. Other CLPs are also described to contain α-helices, including tolaasin, fuscopeptin and 
syringopeptin1. It appears therefore that the α-helix is a common structure among many CLPs, 
suggesting a role of importance for their biological function.  
An important feature of the pseudodesmin A structure is that it is amphipatic. Indeed, all 
hydrophobic and hydrophilic residues in the sequence occur at positions that arrange their side chains 
on opposite sides of the molecule (Figure 5). This includes the three-residue loop region where the L-
D-L stereochemistry allows the hydrophilic D-Ser8 side chain to be oriented towards the opposite side 
of the structure with respect to the hydrophobic L-Leu7 and L-Ile9 side chains. All together, this 
creates a large hydrophobic surface, comprised of all Leu, Ile and Val side chains. A smaller 
hydrophilic surface includes both Ser residues and the Gln residue side chains. The conservation of 
hydrophobic and hydrophilic residues within the viscosin group and the helical part of amphisin and 
tensin (Figure 4) suggests that this amphipaticity is maintained between the different compounds and 
that it plays an important role in their function. 
It has been hypothesized that the biological function and antibiotic mechanism of CLPs is related to 
the formation of passive transport ion channels in the cellular membranes. These will seriously 
destabilize the microorganism’s metabolism by disturbing the ion concentrations in the cytoplasm. 
Within the viscosin group this has been postulated for viscosinamide, which is believed to induce Ca2+ 
transporting pores to inhibit fungal growth13. Furthermore, WLIP has been shown to insert itself 
within model membranes20, while its pore forming capability was demonstrated on erythrocytes using 
osmotic protectants12. The observed properties of pseudodesmin A are in agreement with such 
behaviour. The fact that the compound is practically water insoluble together with the high degree of 
hydrophobic side chains and the fatty acid moiety makes an insertion into the apolar membrane 
plausible. The amphipatic nature of the molecule suggests a model for pore formation that involves the 
formation of reverse type micelles inside the membrane. The molecules pack together with their 
hydrophilic surfaces towards each other while extending the hydrophobic surfaces outward to 
minimize the hydrophobic-hydrophilic contacts with the environment. Independent of the exact 
supramolecular structure that will be formed, these reverse micelles would be able to span the 
membrane, allowing ions to be transported through the hydrophilic pore created. This principle has 
been described previously, for instance for syringomycin21.  
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4. Experimental 
 
4.1 Culture, isolation and purification of pseudodesmin A and B 
 
The original Pseudomonas tolaassii strain was collected from the skin of a black belly salamander 
(Desmognathus quadramaculatus) and was a gift from R. Austin (Plethodon Research, L.L.C., 1590 
Double Springs Road, Demorest, GA 30535, USA). Isolation, preliminary characterization and 
biological screening have been described previously22.  
Following fermentation of the bacterium using standard procedures, the fermentation broth was 
extracted with ethyl acetate, dried over MgSO4 and concentrated in vacuo. The residue was 
redissolved in acetone and a first purification was done using a normal phase open column (Kieselgel 
60, 230-400 mesh ASTM, Merck) with following eluents: hexane/acetone (8/2), hexane/acetone (1/1), 
acetone, and ethanol. The fractions collected after eluting with acetone contained the bioactive 
material. After concentrating, the compound was brought on a preparative TLC (PLC) plate (Silicagel 
60, 20x20cm, 0.5mm layer thickness, Merck) and eluted with dichloromethane/methanol (96/4). The 
fractions were scraped off and the molecules extracted from the silica with methanol. The band 
between Rf values 0 and 0.08 contained the antibacterial molecules. Preliminary LC-MS analysis of 
this fraction showed the strong presence of a molecule with protonated mass [M+H]+ of 1125.3 
Dalton. The LC-MS consisted of a Waters 2690 HPLC with Photodiode Array Detector (Waters 996) 
coupled to a Micromass Q-TOF 2 mass spectrometer. The column used was from Beckman 
(Ultrasphere; C-18; 5 µm, 150×4.6 mm) with guard column 7.5×4.6 mm, packed with the same 
material; eluent: acetonitrile/10mM NH4OAc in water with 0.1% TFA (60/40; flow: 1.5 ml/min); 
detection: 210 nm; retention time: 14.4 minutes (peudodesmin A) or 11.1 minutes (pseudodesmin B), 
measured from the UV chromatograms. MS spectra were taken in positive electrospray ionization 
mode with capillary voltage set at 2.5 kV, the cone voltage at 60 V, a collision energy of 15 eV, the 
microchannel plate at 2150 V, the source temperature at 100°C and the desolvation temperature at 
250°C. The fragmentation of the parent ion (M+H+) was studied via MS/MS analysis in positive 
electrospray ionization mode with a capillary voltage of 2 kV, the cone voltage at 60V and the 
collision energy at 41 eV. The rest of the parameters were the same as mentioned above. For further 
analysis, both compounds, pseudodesmin A and B, were obtained in larger quantities as white solids, 
with yields of 260 mg and 27 mg respectively, which corresponds to 0.163% and 0.0169% of weight 
compared to the collected freeze dried biological material. This is fully described in the supplementary 
data.  
 
4.2 Biological screening 
 
The screening for biological activity involved a selection of pathogens, including bacteria 
(Enterococcus faecalis ATCC 29212/LMG 8222, vancomycin resistant Enterococcus (VRE) ATCC 
700221, Staphylococcus aureus ATCC 29213/LMG 10147, methicillin resistant S. aureus (MRSA) 
ATCC 33591/LMG 16217, Pseudomonas aeruginosa ATCC 27853/LMG 6395, Salmonella 
typhimurium ATCC 700408/LMG 16217, Clostridium perfringens ATCC 13124, Escherichia coli 
ATCC 25922), yeasts (Candida albicans IHEM 10248 ATCC 24433 and Cryptococcus neoformans 
IHEM 9558 ATCC 90112) and one mould (Trichophyton mentagrophytes IHEM 10342/ATCC 9533). 
C. perfringens was obtained from Oxoid as a Culti–Loop culture and grown in Anaerobe Basal broth 
(Oxoid, CM 957), while the other microorganisms were obtained from the Belgian Coordinated 
Collections of Microorganisms (BCCM).  
All the bacteria were grown for 18 hours in Mueller-Hinton broth (MHB, Oxoid, CM 405). Instant 
suspensions were prepared in 5 ml quantities of sterile saline. After standardization according to the 
0.5 McFarland standard, the suspensions were further diluted to a final inoculum of approximately 
5·105 CFU/ml. 
For both the yeasts, a RPMI 1640 broth supplemented with 0.3 g/l glutamine and 34.6 g/l 3-(N-
morpholino)propanesulfonic acid (MOPS-buffer) without bicarbonate was used. The yeasts were then 
sub-cultured at 35°C onto Sabouraud dextrose agar and passaged twice to ensure purity and viability. 
Five colonies of ≥ 1 mm diameter from 24 hour (C. albicans) or 48 hour (C. neoformans) old cultures 
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were picked and suspended in 5 ml of sterile 0.85% saline. The suspension cell densities were then 
standardized to a 0.5 McFarland standard with sterile saline by measuring the transmittance of a 
spectrophotometer at 530 nm. The obtained suspensions of 1-5·106 cells per ml were further diluted to 
obtain a final inoculum of 1-5·103 CFU/ml. 
For the mould, a seven days old culture was covered with approximately 1 ml of sterile 0.85% 
saline. A suspension was made and one drop of Tween 20 was added. The resulting mixture of spores 
and hyphal fragments was transferred to a sterile tube and allowed to settle. The upper homogeneous 
suspension was collected and mixed. The densities of these spore suspensions were then adjusted to an 
optical density (OD) of 75% transmittance at 530 nm. The obtained suspension was further diluted in 
RPMI 1640 broth to obtain a final inoculum of 4·103 to 5·104 CFU/ml.  
The minimum inhibitory concentration (MIC) was determined for both pseudodesmins on every 
pathogen next to a quality positive control compound23, being for the bacteria either vancomycin 
(Fluka/BioChemika 94747) or gentamycin (Fluka/Biochemika 48760) and for the yeasts and the 
mould amphotericin B (Fluka/Biochemika 10047). 2500 ppm solutions in DMSO were obtained of all 
test chemicals and further diluted 10-fold in a 11:1 demineralized water:DMSO mixture. 
A robotic Bioscreen apparatus (Labsystems, Finland) operating under Biolink software was used 
which measures the change in OD (using white light, Wide Band) of the broth culture. Each of the 100 
well honeycomb plates (Labsystems) contained 225 µl MHB (RPMI 1640, 0.3 g/l glutamine and 34.6 
g/l MOPS-buffer without bicarbonate for the mould) and 25 µl of the solvent (negative control), test-
chemical dilution, or positive control. The inoculum was added to the broth, except for the blank tests. 
The bacteria, C. albicans, C. neoformans and the mould were incubated for 16, 24, 48 hours and 5 
days respectively at 35°C (25°C for the mould), with every 20 minutes an OD measurement after 
medium shaking. C. perfringens was incubated under an anaerobic environment purged with CO2. 
Each test was repeated 5 times and the average was calculated. A blank test was performed with 
only the test chemical and MHB in the well and the difference ∆ between the sample and blank areas 
was calculated. Negative control incubation tests were performed in an analogous manner except for 
the absence of test chemicals, resulting in an obtained value ∆NC. The percent of growth was then 
calculated as (∆/∆NC)×100%, which was chosen as critical parameter for the evaluation of possible 
activity. For the mould, instead of kinetic measurements, the difference between final and initial OD 
values was used. Each test was repeated 5 times and the average was calculated.  
In addition, the mixture of pseudodesmin A and B was screened for antiviral and antitumor effects at 
the Rega Institute (K.U. Leuven) against various pathogenic viruses such as human immunodeficiency 
virus (HIV), herpes simplex virus (HSV), vaccinia virus (VV), varicella zoster virus (VZV) and 
human cytomegalovirus (CMV). Antiviral activity was determined as the effective compound 
concentration (EC50) required to inhibit by 50% HIV-induced cytopathicity in human CEM cell 
cultures, HSV- and VV-induced cytopathicity in human embryo fibroblast E6SM cell cultures, VZV-
induced plaque formation in human embryonic lung (HEL) cell cultures and as the concentration 
(IC50) required to inhibit CMV-induced plaque formation by 50% using HEL cells. Antitumor activity 
was determined via the inhibitory effects on the proliferation of murine leukemia cells (L1210/0), 
murine mammary carcinoma cells (FM3A/0) and human T-lymphocyte cells (Molt4/C8, CEM/0). 
 
4.3 LC-MS analysis of the amino acid composition 
 
For this analysis, 6.6 mg of pseudodesmin A was hydrolyzed by dissolving it in 6.6 ml 6 M HCl 
together with 136 mg phenol for 20 hours at 110°C. After solvent evaporation in vacuo, the residue 
was dissolved in 5.28 ml of H2O and 2.29 ml of a 3.7 mM solution of Marfey’s reagent14 in acetone to 
which 528 µl of 1 M NaHCO3 were added to derivatize the free amino acids formed. After stirring this 
mixture for one hour at 40°C, 264 µl of a 2 M HCl solution was added and the solvent was evaporated. 
The residue was dissolved in 8.8 ml DMSO and 60 µl of this solution was diluted to 200 µl with a 
40/60 mixture of acetonitrile/NH4OAc 5 mM. Standard solutions of L- and D-amino acids derivatized 
with Marfey’s reagent were prepared by adding 50 µl 50 mM amino acid aqueous solution to 100 µl of 
3.7 mM Marfey’s reagent in acetone and 20 µl of 1 M NaHCO3. After one hour at 40°C, 10 µl of 2 M 
HCl was added, the solvent was removed in vacuo and the residue was dissolved in 500 µl DMSO. 
This was done separately for several amino acids. By taking 30 µl of every solution, the following 
mixtures were made and diluted to 200 µl with a 40/60 mixture of acetonitrile/NH4OAc 5 mM: D-Leu 
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+ D-Val + D-Thr, L-Leu + L-Val + L-Thr, D-Ile + D-Ser, L-Ile + L-Ser, D-Glu, L-Glu, D-allo-Thr, L-
allo-Thr. All samples were injected on an HPLC column (Ultrasphere C18 5µm, 150×4.6 mm I.D., 
fitted with a precolumn with the same stationary phase, 7.5×4.6 mm I.D.) hyphenated to a UV-detector 
operating at a wavelength of 350 nm for peak integration and a Q-TOF mass spectrometer using 
negative mode electrospray as ionization technique. The mobile phase, acetonitrile/NH4OAc 5 mM, 
was linearly changed from a 10/90 to 28/72 mixture over a time span of 36 minutes.  
 
4.4 NMR Spectroscopy 
 
All NMR measurements were performed on either a Bruker DRX spectrometer operating at 500.13 
MHz and 125.76 MHz for the 1H and 13C frequency respectively, or a Bruker Avance II spectrometer 
operating at 700.13 MHz, 176.05 MHz and 70.94 MHz for 1H, 13C and 15N respectively. In both cases, 
a 1H,13C,15N TXI-Z probe was used. The sample temperature was set to 298.0 K. High quality NE-
HP5-7 (New Era Ent. Inc) NMR tubes were used. Acetonitrile-d3 (99.96%) was purchased from 
Eurisotop, 2D spectra measured for structure elucidation include gradient selected phase sensitive 
DQF-COSY, TOCSY with a 90 ms MLEV-17 spinlock, NOESY with mixing times ranging between 
100 ms and 300 ms, gradient selected 1H-13C gHSQC and 1H-15N gHSQC and gradient selected 1H-13C 
gHMBC. Standard pulse sequences as present in the Bruker library were used throughout24. Typically, 
4096 data points were sampled in the direct dimension for 512 data points in the indirect dimension, 
with the spectral width respectively set to 11 ppm, 170 ppm and 80 ppm along the 1H, 13C and 15N 
dimension. The 1H-13C gHMBC was measured with an 88 ppm 13C spectral width centred on the 
carbonyl chemical shift region. For 2D processing, the spectra were zero filled until a 4096×2048 real 
data matrix. Before Fourier transformation, all spectra were multiplied with a squared cosine bell 
function in both dimensions or sine bell in the direct dimension for the gHMBC. The 1H and 13C 
chemical shifts are referenced against internal TMS, while the 15N chemical shift was referenced 
indirectly to MeNO2 according to IUPAC guidelines25. Scalar couplings were obtained from the 
Gaussian resolution enhanced 1D 1H spectrum.  
 
4.5 Crystal growth and X-Ray structure determination 
 
Following extensive screening, colourless needle-like crystals of pseudodesmin A of sufficient 
quality for X-ray diffraction studies were finally obtained by slow evaporation from a concentrated 
solution in acetonitrile. X-ray data were collected on an Oxford Diffraction Gemini R Ultra 
diffractometer using monochromatic Cu Kα radiation. The data were processed using the CrysAlis 
package (Oxford Diffraction (2007) CrysAlis CCD and CrysAlis RED, versions 1.171.32.5, Oxford 
Diffraction Ltd, Abingdon, Oxfordshire, England). The structure was solved with Sir9226 and refined 
against low temperature data using full-matrix least-squares refinement within SHELXL9727,28 as 
available in the PLATON suite29. All H atoms were calculated geometrically and restrained to ride on 
their parent atoms. A correction for diffuse effects due to the inclusion of disordered solvent molecules 
in the crystal structure was made using the SQUEEZE option of PLATON. The total potential solvent 
volume per unit cell was calculated to be 261 Å3 (4% of the cell volume).  
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Table 1 Antibacterial and antifungal activity 
 
Compound MIC (µg/ml) 
  E. faecalis VRE S. aureus MRSA P. aeruginosa S. typhimurium 
  
ATCC 29212 ATCC 700221 ATCC 29213 ATCC 33591 ATCC 27853 ATCC 700408 
  
LMG 8222   LMG10147 LMG16217 LMG6395 LMG16217 
Pseudodesmin A 3.12-6.25 3.12-6.25 3.12-6.25 6.25-12.5 >25 >25 
Pseudodesmin B 6.25-12.5 3.12-6.25 6.25-12.5 6.25-12.5 >25 >25 
Positive Control 1.0-2.5a >10a 0.1-0.5a 0.5-1.0a 0.1-0.5b 0.1-0.5b 
Compound MIC (µg/ml) 
  E. coli C. perfringens C. albicans C. neoformans T. mentagrophytes 
  
ATCC 25922 ATCC 13124 IHEM 10248 IHEM 9558  IHEM 10342 
    
  ATCC 24433 ATCC 90112 ATCC 9533 
Pseudodesmin A >25 3.12-6.25 >25 >25 >25 
Pseudodesmin B >25 3.12-6.25 >25 >25 >25 
Positive Control 0.1-0.5b 0.25-0.5a 0.75c 0.75c 5c 
The lower value is the highest concentration where inhibition was detected, the higher value is the 
lowest concentration where no inhibition was detected. The maximum concentration tested was 25 
µg/ml. MIC values of positive control compounds were determined in parallel. 
a
 vancomycin 
b
 gentamycin 
c
 amphotericin B 
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Table 2 Antiviral activity and cytotoxic activity 
 
Compound EC50(µg/ml) 
 HIV-1 HIV-2 HSV-1 HSV-2 VV VZV 
 (IIIB) (ROD) (KOS) (G)   
 (CEM) (CEM) (E6SM) (E6SM) (E6SM) (HEL) 
      OKA YS 
Pseudodesmin A+B 7.3 17.3 >16 >16 >16 3 3 
Reference value 0.0063a 0.0097a 0.07b 0.38b 3.2c 0.24b 0.32b 
Compound IC50 (µg/ml) 
 CMV L1210/0 FM3A/0 Molt4/C8 CEM/0 
 AD-169 Davis     
 strain strain     
Pseudodesmin A+B 8 >5 17 16 17 17 
Reference value 1.2d 0.6d -- -- -- -- 
Reference values of standard compounds are provided for comparison23. 
a
 AZT 
b
 Acyclovir 
c
 Brivudin 
d
 Ganciclovir 
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Table 3 1H, 13C and 15N NMR assignments of pseudodesmin A (CD3CN, 298K, 700 MHz) 
 
    
1H δ [ppm] 13C δ [ppm] 15N δ [ppm]     1H δ [ppm] 13C δ [ppm] 15N δ [ppm] 
HDA             Leu5             
    CO 1   175.27   3JHNHα 4.25 Hz NH 37 7.72   -266.48 
    CH2α 2 2.34 / 2.43 44.81       CHα 38 3.97 55.74   
    CHβ 3 3.97 69.53       CO 39       173.62   
    CH2γ 4 1.47 38.27       CH2β 40 1.51 / 1.66 40.71   
    CH2δ 5 1.31 / 1.41 26.36       CHγ 41 1.77 25.53   
    CH2ε 6 1.29 30.20       CH3δ 42 0.87 23.36   
    CH2ζ 7 1.29 30.20       CH3δ 43 0.88 21.34   
    CH2η 8 1.27 32.63   Ser6             
    CH2θ 9 1.29 23.44   3JHNHα 8.47 Hz NH 44 7.11   -276.91 
    CH3ι 10 0.88 14.44       CHα 45 4.32 56.45   
    OH 11 4.40         CO 46       171.93   
Leu1                 CH2β 47 3.81 / 4.15 64.80   
3JHNHα 5.67 Hz NH 12 7.73   -253.87     OHγ 48 4.98     
    CHα 13 3.87 53.92   Leu7             
    CO 14       175.34   3JHNHα 6.53 Hz NH 49 7.10   -260.63 
    CH2β 15 1.65 / 1.74 39.46       CHα 50 4.13 54.90   
    CHγ 16 1.67 25.46       CO 51       173.80   
    CH3δ 17 0.90 22.16       CH2β 52 1.58 / 1.88 42.11   
    CH3δ 18 0.94 23.21       CHγ 53 1.89 25.55   
Gln2                 CH3δ 54 0.90 21.42   
3JHNHα 3.99 Hz NH 19 8.76   -260.90     CH3δ 55 0.99 23.53   
    CHα 20 3.98 57.58   Ser8             
    CO 21       176.63   3JHNHα 9.10 Hz NH 56 7.94   -273.98 
    CH2β 22 2.02 26.35       CHα 57 4.43 57.02   
    CH2γ 23 2.38 32.01       CO 58       171.86   
    COδ 24       176.15       CH2β 59 3.66 / 3.86 63.25   
    NH2 25 5.81 / 6.36   -275.54     OHγ 60 3.80     
Thr3             Ile9             
3JHNHα 7.45 Hz NH 26 8.15   -266.17 3JHNHα 10.70 Hz NH 61 6.68   -270.70 
3JHαHβ 10.71 Hz CHα 27 3.99 61.77       CHα 62 4.56 57.17   
    CO 28       174.33       CO 63       170.12   
    CHβ 29 5.33 70.33       CHβ 64 1.97 36.97   
    CH3γ 30 1.30 18.58       CH3γ 65 0.82 16.28   
Val4                 CH2γ 66 0.97 / 1.15 25.31   
3JHNHα 6.30 Hz NH 31 7.33   -259.73     CH3δ 67 0.86 12.36   
    CHα 32 3.49 65.08   
                
    CO 33       174.63   
                
    CHβ 34 2.17 30.02   
                
    CH3γ 35 0.92 19.56   
                
    CH3γ 36 0.95 21.12   
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Table 4 1H, 13C and 15N NMR assignments of pseudodesmin B (CD3CN, 298K, 700 MHz) 
 
      
1H δ [ppm] 13C δ [ppm] 15N δ [ppm]       1H δ [ppm] 13C δ [ppm] 15N δ [ppm] 
HDA             Leu5             
    CO 1       175.14   3JHNHα 3.99 Hz NH 37 7.77   -266.34 
    CH2α 2 2.35 / 2.43 44.76       CHα 38 3.97 55.75   
    CHβ 3 3.96 69.64       CO 39       173.68   
    CH2γ 4 1.48 38.29       CH2β 40 1.50 / 1.67 40.67   
    CH2δ 5 1.31 / 1.40 26.36       CHγ 41 1.77 25.54   
    CH2ε 6 1.28 30.12       CH3δ 42 0.86 23.36   
    CH2ζ 7 1.28 30.12       CH3δ 43 0.87 21.32   
    CH2η 8 1.26 32.59   Ser6             
    CH2θ 9 1.29 23.44   3JHNHα 8.33 Hz NH 44 7.14   -276.70 
    CH3ι 10 0.88 14.43       CHα 45 4.32 56.47   
    OH 11 3.65         CO 46       172.03   
Leu1              CH2β 47 3.81 / 4.15 64.71   
3JHNHα ND NH 12 7.94   -253.49     OHγ 48 4.99     
    CHα 13 3.89 53.76   Leu7             
    CO 14       175.40   3JHNHα 6.23 Hz NH 49 7.11  -260.54  
    CH2β 15 1.66 / 1.74 39.42       CHα 50 4.14 54.86   
    CHγ 16 1.67 25.45       CO 51       173.88   
    CH3δ 17 0.90 22.15       CH2β 52 1.61 / 1.89 41.90   
    CH3δ 18 0.93 23.25       CHγ 53 1.88 25.56   
Gln2                 CH3δ 54 0.90 21.45   
3JHNHα ND NH 19 8.78   -260.95     CH3δ 55 0.98 23.42   
    CHα 20 3.97 57.62   Ser8             
    CO 21       176.68   3JHNHα 8.96 Hz NH 56 7.95   -273.86 
    CH2β 22 2.01 26.56       CHα 57 4.44 57.10   
    CH2γ 23 2.37 32.14       CO 58       172.02   
    COδ 24       176.09       CH2β 59 3.66 / 3.86 63.29   
    NH2 25 5.82 / 6.42   -275.49     OHγ 60 3.83     
Thr3             Val9             
3JHNHα 7.14 Hz NH 26 8.20   -266.14 3JHNHα 10.01 Hz NH 61 6.71   -271.43 
3JHαHβ 10.68 Hz CHα 27 3.99 61.84       CHα 62 4.52 57.07   
    CO 28       174.34       CO 63       170.15   
    CHβ 29 5.33 70.29       CHβ 64 2.23 30.18   
    CH3γ 30 1.30 18.64       CH3γ 65 0.72 17.21   
Val4                 CH2γ 66 0.82 19.49   
3JHNHα 6.23 Hz NH 31 7.41   -259.52 
                
    CHα 32 3.48 65.10   
                
    CO 33       174.70   
                
    CHβ 34 2.16 30.02   
                
    CH3γ 35 0.90 19.47   
                
    CH3γ 36 0.95 21.27   
                
ND: not determined 
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Table 5 Crystallographic parameters for pseudodesmin A 
 
Crystal data 
Space group Orthorhombic, P212121 
Unit-cell parameters (Ǻ) a=14.174(1), b=18.796(1), 
c=24.423(2) 
V 6506.6(8) Å3 
Z 4 
m 0.71 mm-1 
Crystal size 0.25×0.20×0.10 mm 
Data collection 
Measured reflections 15350 
Independent reflections 8283 
Reflections with I > 2s(I) 6185 
Rint 0.04 
Refinement 
R 0.045 
Reflections 8283 
Parameters 737 
Drmax 0.39 e Å-3 
Drmin -0.24 e Å-3 
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Table 6 φ and ψ torsion angles of pseudodesmin A crystal structure 
 
  Leu1 Gln2 Thr3 Val4 Leu5 Ser6 Leu7 Ser8 Ile9 
φ [°] -60.9 57.1 63.3 61.8 63.1 98.1 -66.4 150.7 -66.0 
ψ [°] 122.7 28.5 40.5 48.6 31.7 1.0 -50.6 -41.2 -6.3 
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Table 7 Overview of pseudodesmin A hydrogen bonds 
 
Intramolecular 
Donor  Acceptor d(D-A) [Ǻ] angle [°] 
Thr3 NH - HDA CO 2.95 152.05 
Leu5 NH - Leu1 CO 3.15 165.35 
Ser6 NH - Gln2 CO 2.82 149.16 
Leu7 NH - Val4 CO 3.18 151.21 
Ser8 NH - Thr3 CO 2.92 168.02 
Intermolecular 
Participants d(D-A) [Ǻ] angle [°] 
HDA OH - Ser6 OHa 2.85 -- 
HDA CO - Ser8 OHa 2.79 160.87 
Leu1 NH - H2Ob 2.83 164.69 
Gln2 NH - Ser8 COa 2.85 164.38 
Val4 CO - Gln2 CONH2c 2.78 168.51 
Leu5 CO - Ile9 NHd 2.93 139.53 
Ser6 CO - H2Oe 2.77 165.73 
Leu7 CO - H2Oe 2.81 151.60 
Hydrogen bonds are considered to have a donor-acceptor bond length of at least 3.4 Ǻ and a bond 
angle of at least 140° 
a
 2nd participant coordinates are (x-1/2,3/2-y,1-z) 
b
 2nd participant coordinates are (x,y,z) 
c
 2nd participant coordinates are (1/2-x,1-y,z-1/2) 
d
 2nd participant coordinates are (1-x,y+1/2,1/2-z) 
e
 2nd participant coordinates are (x+1,y,z) 
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FIGURE LEGENDS 
 
Figure 1: Molecular structure of pseudodesmin A and B. 
 
Figure 2: Crystal structure of pseudodesmin A with ellipsoids representing the B-factors.  
 
Figure 3: Representation of the crystal structure of pseudodesmin A showing only the backbone 
atoms. The helix is shown as a ribbon (N→C from bottom to top), while the Leu7-Ile9 loop can be 
seen making the connection between the helix C-terminal and the Thr3 side chain.  
 
Figure 4: Overview of analogous CLPs to pseudodesmin A and B from both the viscosin and 
amphisin group. The conservation of the hydrophobic and hydrophilic residue positions can clearly be 
observed. 
 
Figure 5: Sphere representation of the crystal structure of pseudodesmin A to illustrate the 
amphipaticity, showing only the side chain atoms starting from CHα. The hydrophobic and 
hydrophilic sides are shown separately, while the α-helix is aligned from bottom to top (N→C) as 
indicated by the arrow. Hydrophobic side chains are coloured green, hydrophilic side chains red and 
the Thr3 residue salmon. The HDA residue is left out for clarity.  
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 2
Experimental procedures on the culturing, isolation and purification of pseudodesmin A and B 
in large quantities 
 
A 100 litre fermentor, equipped with rhuston impellers and baffles to increase the mixing properties 
of the vessel, was used for the fermentation. The seed culture was inoculated with 0.01% of a frozen 
seed stock. One percent of the seed culture was inoculated into the fermentation media prepared with 
essential salts, 3% tryptic soy broth and 0.5% yeast extract. Cultures were incubated for five days at 
28°C ± 1°C. Agitation was adjusted to maintain a dissolved oxygen concentration of 20% throughout 
the duration of the fermentation. The pH of the culture was not controlled. A defoaming agent was 
added during the fermentation. After approximately 19 hours of growth, the fermentor was fed with a 
50% cerelose solution at a rate of 1.0-1.75 g/l·h for the duration of the fermentation. The fermentation 
culture was harvested at 110 hours post inoculation and centrifuged at approximately 10500×g for 15 
minutes at 25°C. The centrate was then concentrated up to 20 fold by hollow fiber filtration (HFF) 
with a 0.2 filter. The retentate was collected and heated to 80°C for 15 minutes and then centrifuged 
again at 13500×g for 15 minutes at 25°C. The centrate was collected, frozen for a minimum of 4 hours 
at -80°C and freeze-dried for a minimum of 5 days. 
The freeze dried material (160 g) was rewetted with 240 ml water and extracted 4 times with ethyl 
acetate. The combined ethyl acetate fractions (total volume of 2.5 litre) were dried in vacuo, which 
gave 2.65 g of residue. The residue was redissolved in ethyl acetate and a first purification was done 
using a normal phase open column (Kieselgel 60, 230-400 mesh ASTM, Merck) with following 
eluents: hexane, hexane/acetone (1/1), acetone, acetone/methanol (9/1), acetone/methanol (1/1) and 
methanol. Those fractions that contained product with a molecular mass of 1124.2 Da (determined via 
LC-MS) were combined. After removal of the solvent in vacuo, the residue (1.07 g) was purified a 
second time using open column normal phase chromatography on Kieselgel 60, eluting consecutively 
with acetone and mixtures of acetone/methanol with ratios (98/2), (95/5) and (90/10). Again those 
fractions that contained product with a molecular mass of 1124.2 Da were combined. In the LC-MS 
chromatogram of the combined fractions, two major peaks could be observed. After the combined 
fractions were concentrated in vacuo, the residue (750 mg) was submitted to preparative HPLC using a 
Gilson 322 pump system equipped with a Beckman Ultrasphere RP-18 column (particle size 5 µm) 
(150×10 mm) was used in order to separate the major peaks. Detection was done with a Gilson 
UV/VIS-156 detector set at wavelength of 210 mm. The eluent used was acetonitrile and water with 
0.1% trifluoroacetic acid (TFA) (ratio 60/40; flow 7.5 ml/min). The total length of one run was 40 
minutes. The peaks eluting at 13 minutes (pseudodesmin B), respectively 23 minutes (pseudodesmin 
A) were collected and yielded 260 mg and 27 mg of pseudodesmin A and B as white solids 
respectively, which corresponds to 0.163% and 0.0169% of weight compared to the collected freeze 
dried biological material.  
 3
1D 1H, 2D 1H-15N HSQC and 1H-13C HSQC spectra with assignments 
 
The following spectra are provided: 
 
• p.4: 700 MHz 1D 1H spectrum of pseudodesmin A in acetonitirle-d3 solution at 298.0 K 
 
• p.5: 700 MHz 1D 1H spectrum of pseudodesmin B in acetonitirle-d3 solution at 298.0 K 
 
• p.6: 700 MHz 2D 1H-15N HSQC spectrum of pseudodesmin A in acetonitirle-d3 solution at 
298.0 K, with assignment of all cross-peaks due to 1JNH correlations 
 
• p.7-8: 700 MHz 2D 1H-13C HSQC spectrum of pseudodesmin A in acetonitirle-d3 solution at 
298.0 K, with assignment of all cross-peaks due to 1JCH correlations 
 
The 700 MHz 1D spectra were recorded with a spectral width of 10.99 ppm, 32768 time domain 
points and an acquisition time of 2.13 s. Before Fourier transform, all spectra were zero filled until 
131072 real data points. No window function was applied. A zero order polynomial baseline 
correction was performed. 
 
All 2D spectra were acquired and processed as described in the main paper. 
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Experimental 
 
Samples 
 
Samples of pseudodesmin A and B were dissolved at 500 ppm in acetonitrile. 
 
Solvents and reagents 
 
Acetonitrile and water were of LC/MS grade from Biosolve (Valkenswaard, The 
Netherlands) and formic acid was supplied by Sigma-Aldrich (Steinheim, Germany).  
 
Analytical instrumentation 
 
HPLC conditions 
 
An Agilent 1200 LC system (Agilent Technologies, Waldbronn, Germany) was used. The 
HPLC column was BEH C18 (Waters, Zellik, Belgium) 100 mm x 2.1 mm ID x 1.7 µm dp, using 
the isocratic mobile phase: formic acid 0.05%/acetonitrile (20/80; v/v) with a mobile phase flow of 
0.3 mL/min. The injection volume was 0.5 µL. 
 
TOF conditions  
 
Agilent LC/MSD TOF mass spectrometer (Agilent Technologies, Waldbronn, Germany). 
Instrument control and data acquisition was performed by Mass Hunter software (Agilent 
Technologies). The analytical conditions are presented in the table 1. 
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Table 1. TOF conditions used for the analysis of the pseudodesmin samples. 
Parameter  Value Parameter  Value 
Min Range (m/z) 700 Max Range (m/z) 1600 
 
Length transients 72864 Abs. Centroid Threshold 
(counts)  
 
500 
Fragmentor (V) 175 Skimmer (V) 
 
60 
OCT RF V (V) 250 Gas Temp (°) 
 
350 
Drying gas (l/min) 9 Nebulizer (psig) 
 
35 
Capillary (V) 3500 Reference mass 
correction  
 
Enable 
Minimum Height 
(counts) 
500 Reference mass list 
(m/z) 
922.009798 
 
1521.971475 
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RESULTS 
 
The chromatogram of the sample pseudodesmin A is shown in figure 1 and the mass 
spectrum is shown in figure 2. The mass spectrum shows ion [M +H]+ with m/z 1125.71396. This 
ion has less than 1 ppm difference of the protonated ion from molecule C54H96N10O15. The data 
for this mass formula calculation is shown in table 2.  
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Figure 1. The chromatogram of the pseudodesmin A. 
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Figure 2. The mass spectra obtained by TOF analysis of the pseudodesmin A. 
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Table 2. Results from the molecule formula calculation of the sample pseudodesmin A. 
Formula (M)  C54H96N10O15 Ion Formula m/z 
 
C54H97N10O15 
Isotope m/z Calc m/z Abund. % Calc. Abund. 
(%) 
Difference 
(ppm) 
Difference 
(mDa) 
 
1 1125.71396 1125.71294 100 100 - 0.91 - 1.02 
 
2 1126.71685 1126.71599 63.76 63.75 - 0.76 - 0.86 
 
3 1127.71964 1127.71879 20.54 23.08 - 0.76 - 0.85 
 
4 1128.72234 1128.72148 3.44 6.08 - 0.76 - 0.86 
 
The chromatogram of the sample pseudodesmin B is shown in figure 3 and the mass 
spectrum in figure 4. The mass spectra shows basically the ion [M +H]+ with m/z 1111.70019. 
This ion has 2.61 ppm difference of the protonated ion from the molecule with formula 
C53H94N10O15. The complete data for this mass formula calculation is shown in table 3.  
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Figure 3. The chromatogram of the pseudodesmin B. 
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Figure 4. The mass spectra obtained by TOF analysis of the pseudodesmin B. 
 
Table 3. Results from the molecule formula calculation of the sample pseudodesmin B. 
Formula (M)  C53H94N10O15 Ion Formula m/z 
 
C53H95N10O15 
Isotope m/z Calc m/z Abund. % Calc. Abund. 
(%) 
Difference 
(ppm) 
Difference 
(mDa) 
 
1 1111.70019 1111.69729 100 100 - 2.61 - 2.90 
 
2 1112.69878 1112.70033 79.99 62.64 1.40 1.55 
 
3 1113.69989 1113.70312 29.61 22.38 2.90 3.23 
 
4 1114.70367 1114.70580 5.22 5.83 1.91 2.13 
 
Conclusion 
 
Based on the TOFMS analyses the molecular formulas C54H96N10O15 for pseudodesmin 
A and C53H94N10O15 for pseudodesmin B were attributed. 
